About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ASH 2021 Conference Coverage on VuMedi
Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
M
ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST Trial: Pelabresib Monotherapy for Myelofibrosis
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
Marina Kremyanskaya
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
Marina Kremyanskaya
81 views
December 20, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
MDS and MPN
06:20
ASH 2021 Conference Coverage on VuMedi
Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…
Feat.
J. Mascarenhas
07:13
ASH 2021 Conference Coverage on VuMedi
FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…
Feat.
J. Mascarenhas
10:26
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Stud…
Feat.
S. Verstovsek
06:04
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…
Feat.
K. Kim
05:14
ASH 2021 Conference Coverage on VuMedi
ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …
Feat.
E. Oliva
11:04
ASH 2021 Conference Coverage on VuMedi
ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …
Feat.
J. Bewersdorf
06:52
ASH 2021 Conference Coverage on VuMedi
ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…
Feat.
S. Verstovsek
11:17
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Management of Polycythemia Vera
Feat.
A. Kuykendall
04:45
ASH 2021 Conference Coverage on VuMedi
ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…
Feat.
A. Jain
08:59
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…
Feat.
M. Shah
08:12
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …
Feat.
A. Yacoub
08:30
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…
Feat.
A. Yacoub
05:32
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…
Feat.
A. Yacoub
08:15
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Highlights in MPN
Feat.
P. Bose
15:25
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…
Feat.
M. Kremyanskaya
10:43
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …
Feat.
P. Bose
05:06
ASH 2021 Conference Coverage on VuMedi
Positioning Fedratinib in the Treatment Strategy of Myelofibrosis
Feat.
F. Passamonti
13:17
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…
Feat.
J. Garcia
12:03
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…
Feat.
A. Brunner
06:27
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…
Feat.
H. Gill
07:56
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…
Feat.
J. Mascarenhas
10:27
Richard T. Silver
Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…
10:44
Aaron Gerds
A Real-World Evaluation of the Association Between Elevated Blood Co…
15:40
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…
Feat.
A. Tefferi
05:15
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…
Feat.
J. Mascarenhas